Independent Replication and Drug-specificity of an Antidepressant Response Polygenic Risk Score
Lin, B.; Arns, M.; Ruttern, B.; Gordon, E.; Lukyx, J.
Show abstract
We here examine associations of a recently published polygenic risk score of antidepressant response (PRS-AR) with antidepressant treatment outcomes (remission and depression score change) in an independent clinical trial. We not only replicate the PRS-AR for escitalopram, but also find antidepressant interaction effects, suggesting drug-specificity of PRS-AR. We therefore also tested the utility of this PRS-AR to stratify between antidepressants and demonstrate a 14% increase in remission rate (from 43.6% to 49.7%), relative to the randomized remission rate.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort 95%
- Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation 94%
- A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping 94%
Similar papers in this journal
- Novel polygenic risk score links depression-related cortical transcriptomic changes to brain morphology and depressive symptoms in men 94%
- Estimating the direct effects of the genetic liabilities to bipolar disorder, schizophrenia, and behavioral traits on suicide attempt using a multivariable Mendelian randomization approach 93%
- Sensitive period-regulating genetic pathways and exposure to adversity shape risk for depression 93%
Similar papers in this journal
- Low predictive power of clinical features for relapse prediction after antidepressant discontinuation in a naturalistic setting 94%
- Atypical depression is associated with a distinct clinical, neurobiological, treatment response and polygenic risk profile 93%
- The genetics of the mood disorder spectrum: genome-wide association analyses of over 185,000 cases and 439,000 controls 93%
Similar papers in this journal
- Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression 93%
- Consistent Differential Effects of Bupropion and Mirtazapine in Major Depression 93%
- Causal influence of dietary habits on the risk of major depressive disorder: A diet-wide Mendelian randomization analysis 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.